The 2019 BIOCELL breast implant recall was a turning point in the public understanding of breast implant safety. On 24 July 2019, after reviewing reports, scientific literature, registries and other safety information, the U.S. Food and Drug Administration (FDA) requested that Allergan recall specific BIOCELL textured breast implants and tissue expanders. Allergan then announced a worldwide voluntary recall of the affected products. The action was connected to an uncommon but serious cancer of the immune system called breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL.
The recall did not mean that every breast implant was unsafe, that every textured implant had the same risk, or that an asymptomatic patient should automatically have an implant removed. Its deeper significance was methodological: a possible safety signal identified years earlier was strengthened by accumulating evidence, communicated publicly, linked to specific products and followed by regulatory action. The episode also showed why breast implant safety surveillance must continue after approval through adverse-event reports, post-approval studies, registries, scientific literature, updated patient labelling and careful clinical assessment.
This article focuses on the recall, how the BIA-ALCL signal developed, what the regulator did, and what the surveillance system means for people who currently have or are considering breast implants. It is an evidence review, not a diagnosis, a product recommendation or a substitute for advice from a qualified healthcare professional. Cosmetic augmentation, reconstruction and tissue-expander populations appear in the evidence, but their risks and clinical contexts are not interchangeable.
What was recalled in 2019?
The recall concerned Allergan’s BIOCELL textured breast implants and textured tissue expanders. The FDA’s notice records the company announcement date as 24 July 2019 and the FDA publication date as 25 July 2019. The affected implant range included both saline-filled and silicone-filled devices, including Natrelle saline products, Natrelle and McGhan 410 anatomically shaped silicone-filled products, Natrelle INSPIRA products and other listed BIOCELL textured styles. The recall also included certain Natrelle 133 and Natrelle 133 Plus textured tissue expanders used in staged reconstruction.
That product detail matters. “BIOCELL” referred to a particular Allergan surface technology and product family; it was not a synonym for all textured implants. Allergan’s notice said that its smooth and MICROCELL products were not affected by that specific recall. Likewise, the recall applied to unused products being removed from distribution. It was not a blanket order for every patient in the world to undergo preventive explantation.
A patient should not try to identify an implant from its age, shape or a photograph. The useful record is the manufacturer, model or style, filler, surface, size, serial or lot information and date of implantation. Those details may be on a patient device card, operative report, implant sticker sheet, patient booklet or the records held by the original surgeon or facility. A product recall is device-specific, so accurate identification is the starting point for a meaningful conversation.
How did the BIA-ALCL safety signal develop?
BIA-ALCL is a rare type of T-cell non-Hodgkin lymphoma. It is not breast cancer. In most reported cases, it develops in the fluid or fibrous scar capsule surrounding a breast implant, although it can extend beyond that local space. The FDA first identified a possible association between breast implants and ALCL in 2011, when too few cases were known to determine the main risk factors reliably.
The signal did not come from one perfect trial. It developed through several imperfect but complementary streams of information: individual medical-device reports, published case reports and case series, post-approval study data, patient-specific registries, reports from clinicians and discussions with patients and professional groups. By 2016, the World Health Organization had recognised BIA-ALCL as a distinct form of ALCL associated with breast implants, while also acknowledging that worldwide case counts were difficult to establish because reporting was incomplete and global implant-use denominators were limited. The earlier regulatory context is discussed in our evidence review of FDA breast implant regulation and the 1992 moratorium.
As the evidence accumulated, a consistent association with textured surfaces became more apparent than with smooth surfaces. The association was not identical across textured products. Surface roughness, manufacturing method, pore characteristics, device design, market share, exposure time and the completeness of the implant history can all affect the apparent pattern. A regulator therefore has to answer two different questions: is there a credible device-related safety signal, and is the available evidence specific enough to justify action against a particular product or category? The technical background to these distinctions is covered in the planned review of breast implant surface technology history.
Why did the FDA ask Allergan to recall BIOCELL?
On 24 July 2019, the FDA stated that its analysis of newly submitted global safety information showed that the risk of BIA-ALCL with Allergan BIOCELL textured implants was approximately six times the risk associated with textured implants from other manufacturers marketing in the United States. The agency described the overall incidence as relatively low, but considered the evidence sufficient to conclude that the continued availability of the specific products posed a public-health concern. Allergan responded with a voluntary worldwide recall of the affected BIOCELL implants and tissue expanders.
This was a proportionate regulatory response to a product-specific signal, not a claim that all textured devices were equivalent. The FDA also issued information for patients and clinicians describing symptoms, the listed models and the recommended approach to asymptomatic patients. The agency explained that it had been monitoring the issue since 2011 and had used reports, external registries and scientific literature in evaluating the signal. It also said that manufacturers would be expected to provide regular trend information and report adverse events through established systems.
The recall illustrates an important distinction between a hazard signal and an individual diagnosis. A higher reported association does not tell a particular patient that she has BIA-ALCL. Conversely, the rarity of the condition does not justify ignoring a late, unexplained change. The correct response depends on the individual device history, symptoms, examination and, when indicated, imaging and laboratory assessment.
What did the recall mean for patients without symptoms?
The FDA did not recommend routine removal or replacement of BIOCELL or other textured breast implants in patients who had no symptoms. The reason is that surgery has its own risks, while preventive removal of an asymptomatic implant was not judged to have a favourable balance for every patient. This advice was not a declaration that the device was risk-free. It was guidance against an automatic operation based only on the existence of a recall or on fear about a rare disease.
An individual may still discuss removal, replacement or observation with a qualified surgeon. Relevant factors can include the exact implant model and surface, the patient’s previous breast operations, personal risk tolerance, current breast findings, the condition of the capsule, access to follow-up and the possible aesthetic or physical changes after surgery. A patient with a confirmed diagnosis is in a different category: treatment generally involves removal of the implant and surrounding capsule under specialist guidance, and the operation should be planned around the confirmed disease rather than a general preventive rule.
It is also important not to confuse BIA-ALCL monitoring with routine breast-cancer screening or silicone-implant rupture screening. These are different clinical questions. A mammogram, ultrasound or MRI may be used for different reasons, and the appropriate test depends on the symptom, the implant filler, the patient’s age and breast-cancer risk, and the clinician’s assessment. A late swelling or mass should not be dismissed simply because a patient has recently had another type of imaging.
Which symptoms should prompt assessment?
The FDA identifies persistent swelling, a mass or pain in the area of the implant as the main symptoms that should be assessed. These changes often occur years after the original operation, when the incision itself has long healed. A late fluid collection, a new breast enlargement on one side, a lump, increasing firmness or a significant change in shape can have many causes, including rupture, capsular contracture, infection, trauma, benign fluid or another breast condition. The symptom does not prove BIA-ALCL, but it deserves a clinical explanation.
Assessment usually begins with a history and physical examination. Depending on the findings, a clinician may request ultrasound or another imaging test. If fluid is present around the implant, it may be sampled for appropriate cytological and immunohistochemical testing, including assessment for markers such as CD30 and ALK when BIA-ALCL is suspected. Tissue from a mass or capsule may also require specialist pathology. The purpose is not to label every late seroma as lymphoma; it is to avoid missing a serious diagnosis and to choose the right treatment if one is confirmed.
Patients should not attempt to drain a swelling, remove an implant or arrange an incomplete “capsule clean-out” without medical advice. An unplanned procedure can complicate diagnosis and may not address the underlying problem. The practical guide to BIA-ALCL symptoms and patient questions can help a reader prepare for that discussion, but it cannot replace examination or testing. If the original surgeon is unavailable, the patient can bring the device card and operative records to a plastic surgeon, breast surgeon or multidisciplinary team familiar with implant-related complications.
What does breast implant safety surveillance actually involve?
Safety surveillance, also called post-market or postmarket surveillance, is the continuing process of looking for problems after a medical device is being used in a larger and more diverse population than the original approval studies. Approval is based on the evidence available at a particular time. It does not close the evidence process, especially for an implanted device that can remain in the body for many years.
One part of surveillance is the FDA’s Medical Device Reporting system, or MDR. Manufacturers, importers and certain healthcare facilities report qualifying device-related adverse events and product problems. MDRs can help identify a pattern that deserves investigation, but they cannot by themselves calculate the incidence or prevalence of BIA-ALCL. Reports may be under-reported, duplicated, incomplete, inaccurate, unverified or affected by the absence of a reliable denominator showing how many people use each product. A report also does not prove that the device caused the event.
That limitation is not a reason to disregard MDRs. It is a reason to interpret them alongside other evidence. Regulators also review scientific literature, manufacturer post-approval studies, registries, manufacturing or design information, clinical discussions and reports from other countries. The PROFILE registry, developed through collaboration involving the American Society of Plastic Surgeons and the Plastic Surgery Foundation, is one example of an implant-specific effort to improve understanding of BIA-ALCL’s causes, presentation and treatment. Different data sources answer different questions; agreement across sources can strengthen a signal, while disagreement can reveal where better data are needed.
Current FDA information shows this continuing process. The agency’s postmarket page describes its review of manufacturer compliance with post-approval requirements, study enrolment and follow-up, MDRs, annual reports, manufacturing changes and updated study findings. The FDA also maintains product-specific labelling and post-approval study information. In other words, surveillance is not only a crisis response. It is routine evidence generation that can change what patients are told about a device over time.
How did the 2019 recall change patient communication?
The recall made the device surface and the patient’s long-term information record much more visible. In September 2020, the FDA issued final labelling recommendations covering a boxed warning, a patient decision checklist, a description of materials, silicone-gel rupture screening information and a patient device card. On 27 October 2021, the FDA approved updated labelling and took actions restricting sale and distribution to healthcare providers and facilities that provide the required risk information. The checklist must be reviewed with the prospective patient, who must have the opportunity to initial and sign it, and the implanting physician must also sign it.
These changes are not paperwork for its own sake. They recognise that a patient needs information that remains useful after leaving the operating theatre: the exact device, known complications, the possibility of further surgery, monitoring questions and where to find current product information. The FDA’s approved-labelling page distinguishes original labelling from current labelling updated with post-approval evidence. Patients should therefore keep their device card and request the current manufacturer booklet for the exact model rather than relying on a generic description such as “silicone implant” or “textured implant.”
The communication model also became broader than BIA-ALCL. In a March 2023 update, the FDA described reports of squamous cell carcinoma (SCC) and various lymphomas other than BIA-ALCL in the scar capsule around breast implants. The notice reported 19 SCC cases in the published literature at that time, including three deaths, and stressed that the cases were rare and that information remained limited. The FDA did not recommend implant removal solely because of concern about these rare cancers. This later communication shows how surveillance can expand when a new signal appears, without converting preliminary reports into a universal diagnosis or a reason for automatic surgery.
What should a current patient do now?
- Identify the device. Find the manufacturer, model or style, filler, surface and implantation date. Keep the patient device card and operative report in a secure place.
- Use current information. Check the manufacturer’s current patient labelling and the safety communications of the regulator relevant to the country where the implant was supplied or where care is being provided.
- Report a late change. Persistent swelling, a mass, ongoing pain or a substantial new asymmetry should be assessed, particularly when it develops years after surgery.
- Do not self-triage a recall. A recalled or discontinued product is not the same as a confirmed complication. A clinician should explain the device-specific advice and the risks of any proposed operation.
- Plan continuity of care. If surgery took place abroad or the original clinic is no longer available, provide the new clinician with all records and explain the original procedure, any previous implant exchanges and any recent changes.
For someone considering breast augmentation, the practical lesson is to ask for the exact implant information before consent, not only the brand name or an approximate volume. The site’s breast augmentation operation and implant-planning information provides procedural context, while the smooth versus textured breast implants guide explains the surface discussion in plain language. The surgeon should explain why the device and surface are being proposed, what complications can occur, what symptoms need review and how records will be supplied after surgery. The FDA’s risk communication materials are a useful benchmark, but the advice of the regulator and healthcare team in the relevant country must also be considered.
Evidence limitations and responsible interpretation
The 2019 recall was based on an evolving body of evidence rather than a randomised comparison of every implant on the market. BIA-ALCL is rare, and the number of implanted devices, duration of exposure and completeness of historical records are not known equally across countries. Passive reports can contain duplicates and missing data. Reported cases are not a risk calculation, and the proportion of cases attributed to a manufacturer cannot be interpreted without knowing product use, referral patterns and prior implant history.
Surface terms are also not perfectly interchangeable. “Textured” includes products with different roughness, pore structure and manufacturing methods. A conclusion about BIOCELL should not automatically be applied to every textured product, just as a smooth surface should not be described as a guarantee against every implant complication. Evidence from reconstruction, tissue expanders and cosmetic augmentation may answer different clinical questions.
Finally, regulator information can change. The statistics and product tables on an official website have an update date and may be revised as reports are clarified. The figures in this article are therefore presented with their source dates, not as timeless estimates. Patients should verify current product-specific information and obtain individual medical assessment for a new symptom or a decision about removal or replacement.
Frequently asked questions
What was the 2019 BIOCELL breast implant recall?
It was Allergan’s voluntary worldwide recall of specified BIOCELL textured breast implants and tissue expanders after the FDA identified a higher association with BIA-ALCL. It did not apply to every breast implant or every textured product, and it was not a universal instruction for asymptomatic patients to have implants removed.
Does the BIOCELL recall mean that every textured implant must be removed?
No. The FDA does not recommend routine removal of breast implants in patients without symptoms solely because of concern about BIA-ALCL. The exact device, the patient’s history, current findings and the risks of surgery should be discussed with a qualified surgeon. A confirmed diagnosis requires a different specialist treatment pathway.
What are the main symptoms of BIA-ALCL?
Persistent swelling, a new mass or ongoing pain around an implant are the main symptoms described by the FDA. They may appear years after implantation. These findings have other possible causes, so they do not prove lymphoma, but they should be assessed rather than watched indefinitely without medical advice.
Can BIA-ALCL occur with a saline implant?
Yes. BIA-ALCL is associated more strongly with textured surface exposure than with the filler alone. The FDA’s recall included both saline-filled and silicone-filled BIOCELL devices, and its patient information states that current data do not establish implant fill as the main risk factor. The exact device and surface history remain important.
How can a patient find out whether an implant was BIOCELL?
Check the patient device card, operative report, implant sticker sheet or manufacturer booklet for the manufacturer, model or style, surface and serial or lot information. If the records are missing, contact the original surgeon or facility, or ask a qualified clinician to help reconstruct the device history. Do not identify a product from its appearance or implantation year alone.
What does breast implant safety surveillance mean for current patients?
It means that regulators, manufacturers and clinicians continue to review adverse-event reports, scientific literature, registries and post-approval studies after a device reaches the market. Patients can support safe care by keeping device records, reporting new symptoms promptly and attending appropriate clinical assessments. Surveillance does not mean that every reported event was caused by an implant or that every patient needs the same action.
Sources and references
- U.S. Food and Drug Administration: Allergan Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders — recall notice, affected product family, dates and advice for asymptomatic patients.
- U.S. Food and Drug Administration: FDA takes action to protect patients from risk of certain textured breast implants — 24 July 2019 regulatory announcement, evidence review and manufacturer-specific risk comparison.
- U.S. Food and Drug Administration: Questions and Answers about BIA-ALCL — disease definition, symptoms, surface association, evaluation, patient advice and reporting.
- U.S. Food and Drug Administration: Medical Device Reports of BIA-ALCL — MDR methodology, limitations and tables updated with data received through 30 June 2024.
- U.S. Food and Drug Administration: Breast Implant Postmarket Safety Information — postmarket evaluation, manufacturer studies, MDR review and post-approval study information.
- U.S. Food and Drug Administration: Labeling for Approved Breast Implants — current versus original labelling, 2020 recommendations and 2021 communication requirements.
- U.S. Food and Drug Administration: Breast Implant Surgery — patient device card, checklist, consultation questions and current safety communication.
- U.S. Food and Drug Administration, CDRH: Updates Safety Communication for Squamous Cell Carcinoma in Scar Tissue around Breast Implants — 8 March 2023 update illustrating continued surveillance of rare capsule cancers beyond BIA-ALCL.
- U.S. Food and Drug Administration: Risks and Complications of Breast Implants — current overview of implant complications, BIA-ALCL, other rare reported cancers and imaging information.